P

PT UBC Medical Indonesia Tbk
IDX:LABS

Watchlist Manager
PT UBC Medical Indonesia Tbk
IDX:LABS
Watchlist
Price: 150 IDR -0.66% Market Closed
Market Cap: Rp592.5B

PT UBC Medical Indonesia Tbk
Investor Relations

PT UBC Medical Indonesia Tbk is a ID-based company operating in Health Care Providers & Services industry. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 64 full-time employees. The company went IPO on 2024-07-10. PT UBC Medical Indonesia Tbk is an Indonesia-based medical diagnostic company. The firm provides affordable medical diagnostic tests and instruments for the Indonesian healthcare market. The firm operates through two segments: Medical disposable and consumables, and Diagnostic and equipment. The company offers various products to detect and diagnose various diseases, such as tuberculosis, cervical cancer, newborn screening, COVID-19, health risk screening with artificial intelligence (AI) and molecular systems. Its products include NeoMoDX Molecular System, Airdoc, QIAstat-DX Analyzer, Care HPV System, Hybrid Capture 2 - HPV DNA Test, Revvity SARS-COV-2 RT PCR, Geneproof SARS-COV-2 PCR KIT, Quantiferon TB Gold Plus, Genoscholar, Ina TB, GSP Neonatal Kit, Delfia Neonatal Kit, Neonatal Sampling Paper and Victor2 D.

Show more
Loading
LABS
Jakarta Composite Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Franciscus Xaverius Yoshua Raintjung
Corporate Secretary & President Director
No Bio Available
Mr. Marcella Angelin
Director of Finance & Director
No Bio Available
Muhammad Fajar Shodiq
Chief of Internal Audit Unit
No Bio Available

Contacts

Address
DKI JAKARTA
Jakarta Timur
Gedung Etana Lt.3, Jl. Rawagelam V L, No Kav 11-13, Kel. Jatinegara Kec
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett